This information was published on 2025-07-07T08:15:59 for IP Right Registration Published.
| Field | Value |
| (210) | 2475501 |
| (220) |
20 Aug 2024
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment of rare genetic diseases; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceutical preparations containing biomedical compounds comprised of ribonucleic acid polymers for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use in RNA editing; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use in base editing; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases Class 40 Custom manufacture of biomedical compounds comprised of nucleotide polymers or biomedical compounds comprised of ribonucleic acid polymers for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders Class 42 Pharmaceutical research and development; Pharmaceutical research and development in the fields of gene therapies, gene editing, drug discovery and development; Research and development of pharmaceutical products; Research and development in the field of bioscience; Research and development of biomedical compounds comprised of nucleotide polymers for use in targeted pharmaceutical therapies for the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders; Research and development of pharmaceutical preparations for the treatment of liver-based disorders, eye disorders and CNS disorders; Research and development of biomedical compounds comprised of nucleotide polymers for targeted RNA editing; Research and development of oligonucleotide drug platforms for use in the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders |
| (540) | KORRO BIO |
| (550) | Word |
| (730) |
Korro Bio, Inc.
|
| (750) |
PHILLIPS ORMONDE FITZPATRICK
|
Find out more about publications on the About page.